NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
1-15 of 347
Proactive Pregnancy Planning and Reproductive Care in MS
NeuroFrontiersProactive Pregnancy Planning and Reproductive Care in MS
Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
NeuroFrontiersApplying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis
Emerging Serum microRNAs as Early Signals in MS
NeuroFrontiersEmerging Serum microRNAs as Early Signals in MS
Advancing Pediatric MS Care: Insights from AAN 2026
NeuroFrontiersAdvancing Pediatric MS Care: Insights from AAN 2026
- advertisement
Family Planning in Patients with Multiple Sclerosis
NeuroFrontiersFamily Planning in Patients with Multiple Sclerosis
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiersEarly ALS Patients Show Slowed Decline with Pridopidine Treatment
Rethinking Progression in Multiple Sclerosis
NeuroFrontiersRethinking Progression in Multiple Sclerosis
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiersThe Burden of Cognitive Dysfunction in Multiple Sclerosis
- advertisement
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiersWho’s Missing from Multiple Sclerosis Research?
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiersGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiersCK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses









































